Emily C Edmonds1, Denis S Smirnov2, Kelsey R Thomas2, Lisa V Graves2, Katherine J Bangen2, Lisa Delano-Wood2, Douglas R Galasko2, David P Salmon2, Mark W Bondi2. 1. From the Veterans Affairs San Diego Healthcare System (E.C.E., K.R.T., L.V.G., K.J.B., L.D.-W., D.R.G., M.W.B.); and Departments of Psychiatry (E.C.E., K.R.T., L.V.G., K.J.B., L.D.-W., M.W.B.) and Neurosciences (D.S.S., D.R.G., D.P.S.), University of California San Diego, La Jolla. ecedmonds@ucsd.edu. 2. From the Veterans Affairs San Diego Healthcare System (E.C.E., K.R.T., L.V.G., K.J.B., L.D.-W., D.R.G., M.W.B.); and Departments of Psychiatry (E.C.E., K.R.T., L.V.G., K.J.B., L.D.-W., M.W.B.) and Neurosciences (D.S.S., D.R.G., D.P.S.), University of California San Diego, La Jolla.
Abstract
BACKGROUND AND OBJECTIVES: Given prior work demonstrating that mild cognitive impairment (MCI) can be empirically differentiated into meaningful cognitive subtypes, we applied actuarial methods to comprehensive neuropsychological data from the University of California San Diego Alzheimer's Disease Research Center (ADRC) in order to identify cognitive subgroups within ADRC participants without dementia and to examine cognitive, biomarker, and neuropathologic trajectories. METHODS: Cluster analysis was performed on baseline neuropsychological data (n = 738; mean age 71.8). Survival analysis examined progression to dementia (mean follow-up 5.9 years). CSF Alzheimer disease (AD) biomarker status and neuropathologic findings at follow-up were examined in a subset with available data. RESULTS: Five clusters were identified: optimal cognitively normal (CN; n = 130) with above-average cognition, typical CN (n = 204) with average cognition, nonamnestic MCI (naMCI; n = 104), amnestic MCI (aMCI; n = 216), and mixed MCI (mMCI; n = 84). Progression to dementia differed across MCI subtypes (mMCI > aMCI > naMCI), with the mMCI group demonstrating the highest rate of CSF biomarker positivity and AD pathology at autopsy. Actuarial methods classified 29.5% more of the sample with MCI and outperformed consensus diagnoses in capturing those who had abnormal biomarkers, progressed to dementia, or had AD pathology at autopsy. DISCUSSION: We identified subtypes of MCI and CN with differing cognitive profiles, clinical outcomes, CSF AD biomarkers, and neuropathologic findings over more than 10 years of follow-up. Results demonstrate that actuarial methods produce reliable cognitive phenotypes, with data from a subset suggesting unique biological and neuropathologic signatures. Findings indicate that data-driven algorithms enhance diagnostic sensitivity relative to consensus diagnosis for identifying older adults at risk for cognitive decline.
BACKGROUND AND OBJECTIVES: Given prior work demonstrating that mild cognitive impairment (MCI) can be empirically differentiated into meaningful cognitive subtypes, we applied actuarial methods to comprehensive neuropsychological data from the University of California San Diego Alzheimer's Disease Research Center (ADRC) in order to identify cognitive subgroups within ADRC participants without dementia and to examine cognitive, biomarker, and neuropathologic trajectories. METHODS: Cluster analysis was performed on baseline neuropsychological data (n = 738; mean age 71.8). Survival analysis examined progression to dementia (mean follow-up 5.9 years). CSF Alzheimer disease (AD) biomarker status and neuropathologic findings at follow-up were examined in a subset with available data. RESULTS: Five clusters were identified: optimal cognitively normal (CN; n = 130) with above-average cognition, typical CN (n = 204) with average cognition, nonamnestic MCI (naMCI; n = 104), amnestic MCI (aMCI; n = 216), and mixed MCI (mMCI; n = 84). Progression to dementia differed across MCI subtypes (mMCI > aMCI > naMCI), with the mMCI group demonstrating the highest rate of CSF biomarker positivity and AD pathology at autopsy. Actuarial methods classified 29.5% more of the sample with MCI and outperformed consensus diagnoses in capturing those who had abnormal biomarkers, progressed to dementia, or had AD pathology at autopsy. DISCUSSION: We identified subtypes of MCI and CN with differing cognitive profiles, clinical outcomes, CSF AD biomarkers, and neuropathologic findings over more than 10 years of follow-up. Results demonstrate that actuarial methods produce reliable cognitive phenotypes, with data from a subset suggesting unique biological and neuropathologic signatures. Findings indicate that data-driven algorithms enhance diagnostic sensitivity relative to consensus diagnosis for identifying older adults at risk for cognitive decline.
Authors: Emily C Edmonds; Alexandra J Weigand; Kelsey R Thomas; Joel Eppig; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: J Int Neuropsychol Soc Date: 2018-09 Impact factor: 2.892
Authors: Mary M Machulda; Emily S Lundt; Sabrina M Albertson; Walter K Kremers; Michelle M Mielke; David S Knopman; Mark W Bondi; Ronald C Petersen Journal: Alzheimers Dement Date: 2019-05-23 Impact factor: 21.566
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Kumar B Rajan; Lisa L Barnes; Robert S Wilson; Elizabeth A McAninch; Jennifer Weuve; Dominique Sighoko; Denis A Evans Journal: J Am Geriatr Soc Date: 2017-09-12 Impact factor: 5.562
Authors: R C Petersen; P S Aisen; L A Beckett; M C Donohue; A C Gamst; D J Harvey; C R Jack; W J Jagust; L M Shaw; A W Toga; J Q Trojanowski; M W Weiner Journal: Neurology Date: 2009-12-30 Impact factor: 9.910
Authors: Joel S Eppig; Emily C Edmonds; Laura Campbell; Mark Sanderson-Cimino; Lisa Delano-Wood; Mark W Bondi Journal: J Int Neuropsychol Soc Date: 2017-06-05 Impact factor: 2.892
Authors: Erin E Sundermann; Mark W Bondi; Laura M Campbell; Ben Gouaux; Raeanne C Moore; Virawudh Soontornniyomkij; David J Moore Journal: J Infect Dis Date: 2021-08-02 Impact factor: 5.226
Authors: Lisa V Graves; Emily C Edmonds; Kelsey R Thomas; Alexandra J Weigand; Shanna Cooper; Mark W Bondi Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Una Smailovic; Daniel Ferreira; Birgitta Ausén; Nicholas James Ashton; Thomas Koenig; Henrik Zetterberg; Kaj Blennow; Vesna Jelic Journal: Front Aging Neurosci Date: 2022-04-08 Impact factor: 5.750
Authors: Lauren E Kenney; Adrianna M Ratajska; Francesca V Lopez; Catherine C Price; Melissa J Armstrong; Dawn Bowers Journal: Brain Sci Date: 2021-12-30